Philip W. Kantoff, Jones T. Nauseef and Richard Messmann

Philip Kantoff, MD, is a globally recognized leader in prostate cancer research and treatment. He serves as Co-founder and CEO of Convergent Therapeutics and previously held leadership roles at Dana-Farber Cancer Institute, where he directed the Lank Center for Genitourinary Oncology and was Chief of Solid Tumor Oncology. He later served as Chair of Medicine at Memorial Sloan Kettering Cancer Center. Dr. Kantoff has led multiple pivotal clinical trials that have shaped the standard of care in prostate cancer, including work spanning androgen signaling inhibitors, immunotherapy, and radiopharmaceuticals. His research has focused on the biology and clinical management of advanced prostate cancer, with particular emphasis on treatment sequencing and emerging therapeutic modalities.

Richard Messmann, MD is a medical oncologist and clinical research physician with over 30 years of drug development experience, focused on radiotherapeutics, immuno-therapeutics, cytotoxic conjugates, and small molecule cell signal transduction inhibitors. After completing a medical oncology fellowship at the National Cancer Institute, he served as deputy associate director of the NIH/NCI’s Developmental Therapeutics Program (DTP). During and after Novartis’s 2018 acquisition of Endocyte, Inc. he led the clinical team responsible for the global development and registration of lutetium Lu 177 vipivotide tetraxetan (Pluvicto) and gallium Ga 68 gozetotide (Locametz).

Jones T. Nauseef, MD PhD is a medical oncologist and physician-scientist who has focused his career on advanced prostate cancers, with emphasis on patient care, drug development, radiopharmaceuticals, and genomics. He holds a PhD in Molecular Physiology and Biophysics. He serves currently as the Executive Medical Director for Convergent Therapeutics, Inc. and holds a courtesy appointment as Assistant Professor of Medicine at Weill Cornell Medicine.